Euroapi(0EAP)
EUR --+0.00%
Reward55Moderate
Risk53Moderate
📊25%Data
Thin -25% profit margin · Revenue down 6% YoY
0EAP
+0.0 · +0.00%
EUR · LSE
Euroapi |
Balanced
Market Cap:
ℹ️
Reward Rating
55
Moderate
Bottom 50% (model universe)
25% data coverage
ℹ️
Risk Rating
53
Moderate
Risk Assessment
50% data coverage
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on 0EAP to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Euroapi?

develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally.

0EAP · Verdict

Solid reward · elevated risk

0EAP sits in line with its peers across most factors — no standout strengths or weaknesses.

Based on 38% data coverage

0EAP · Verdict

What’s working & what to watch

Model-based scoring. For information only — not financial advice.

What is Euroapi?

develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally. The company offers contract development manufacturing organization for different classes of tides that uses solid phase chemistry; particle engineering; microbial fermentation; small molecules synthesis; prostaglandins; steroids and hormones; and opiates and controlled substances. The company is listed on the LSE in UK.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Adequate profitability with some margin variability in recent periods.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (55)

The scoring profile indicates moderate reward potential, with valuation and growth as the leading contributors. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorN/A
Market CapN/A
P/E RatioN/A
Dividend YieldN/A
52 Week High3.53
52 Week Low1.24
Last AnnualDecember
IPO DateN/A
IncorporatedUK
Shares OutstandingN/A
No. of Employees2,961
IndustryN/A
ExchangeLSE
Beta0.949
CurrencyEUR